Literature DB >> 7503695

Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus.

S J Dunn1, L Fiore, R L Werner, T L Cross, R L Broome, F M Ruggeri, H B Greenberg.   

Abstract

Rhesus rotavirus (RRV) VP4 trypsin cleavage product VP5(1)*, a truncated form of VP5*, was expressed in baculovirus and found by immunoprecipitation to be antigenically similar to VP5* on the virion. Immunization of mice with VP5(1)* elicited neutralizing antibody that was found to be cross-reactive with viruses representing P genotypes 1, 3, 4, 6, 7, and 8. Baculovirus expressed trypsin cleavage products, VP8* (amino acids 1-246) and VP5(1)* (amino acids 247-474), were tested for their ability to elicit a protective response in a murine model of passive protection. These results were compared to those obtained with baculovirus expressed RRV VP4. Dams immunized with baculovirus expressed RRV VP4 gave birth to pups protected from RRV virus challenge. Neither VP5(1)* nor VP8* was as effective at generating protective immunity as full length VP4. However, antibody to VP5(1)* was more effective than antibody to VP8* at mediating protection even though the neutralizing antibody titers as measured by hemagglutination inhibition and focus reduction neutralization were similar.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503695     DOI: 10.1007/bf01322686

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  20 in total

1.  Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant.

Authors:  M Gorziglia; A Z Kapikian
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.

Authors:  P A Offit; R D Shaw; H B Greenberg
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

Review 3.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

4.  Serotypic analysis of VP3 and VP7 neutralization escape mutants of rhesus rotavirus.

Authors:  R D Shaw; E R Mackow; M L Dyall-Smith; I Lazdins; I H Holmes; H B Greenberg
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

5.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4.

Authors:  S M Matsui; P A Offit; P T Vo; E R Mackow; D A Benfield; R D Shaw; L Padilla-Noriega; H B Greenberg
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

6.  The rhesus rotavirus outer capsid protein VP4 functions as a hemagglutinin and is antigenically conserved when expressed by a baculovirus recombinant.

Authors:  E R Mackow; J W Barnett; H Chan; H B Greenberg
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge.

Authors:  E R Mackow; P T Vo; R Broome; D Bass; H B Greenberg
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

8.  Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy.

Authors:  B V Prasad; J W Burns; E Marietta; M K Estes; W Chiu
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

9.  Three-dimensional structure of rhesus rotavirus by cryoelectron microscopy and image reconstruction.

Authors:  M Yeager; K A Dryden; N H Olson; H B Greenberg; T S Baker
Journal:  J Cell Biol       Date:  1990-06       Impact factor: 10.539

10.  Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.

Authors:  L Padilla-Noriega; L Fiore; M B Rennels; G A Losonsky; E R Mackow; H B Greenberg
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

View more
  4 in total

1.  Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Jianping Li; Shousun Szu; Yasutaka Hoshino
Journal:  Vaccine       Date:  2012-08-09       Impact factor: 3.641

2.  A G3P[13] porcine group A rotavirus emerging in China is a reassortant and a natural recombinant in the VP4 gene.

Authors:  Z Jing; X Zhang; H Shi; J Chen; D Shi; H Dong; L Feng
Journal:  Transbound Emerg Dis       Date:  2017-11-16       Impact factor: 5.005

3.  Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs.

Authors:  Ashwin Ramesh; Jiangdi Mao; Shaohua Lei; Erica Twitchell; Ashton Shiraz; Xi Jiang; Ming Tan; And Lijuan Yuan
Journal:  Vaccines (Basel)       Date:  2019-11-06

4.  Bivalent rotavirus VP4∗ stimulates protective antibodies against common genotypes of human rotaviruses.

Authors:  Guoxing Luo; Yuanjun Zeng; Han Yang; Yijian Li; Lianwei Yang; Cao Li; Feibo Song; Shiyin Zhang; Tingdong Li; Shengxiang Ge; Jun Zhang; Ningshao Xia
Journal:  iScience       Date:  2022-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.